{"id":"NCT00264797","sponsor":"University of Cincinnati","briefTitle":"Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)","officialTitle":"Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2005-12-13","resultsPosted":"2013-06-07","lastUpdate":"2013-06-07"},"enrollment":303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD","Substance Abuse"],"interventions":[{"type":"DRUG","name":"Methylphenidate (OROS-MPH)","otherNames":[]},{"type":"DRUG","name":"Methylphenidate (OROS-MPH) - Placebo","otherNames":[]}],"arms":[{"label":"Methylphenidate","type":"ACTIVE_COMPARATOR"},{"label":"Methylphenidate (Placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.","primaryOutcome":{"measure":"ADHD Severity","timeFrame":"baseline and 20 weeks","effectByArm":[{"arm":"Methylphenidate","deltaMin":-20.6,"sd":11.1},{"arm":"Methylphenidate (Placebo)","deltaMin":-21.8,"sd":11.9}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["21871372","22889694"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":151},"commonTop":["Headache","Abdominal Pain Upper","Nasopharyngitis","Pharyngolaryngeal Pain","Insomnia"]}}